Evidence map›Paper›PMID 40464542›Full record

ArticleJournal of medicinal chemistry2025

Characterization of Hepatotropic Small Molecule Inhibitors of Hypoxia Inducible Factor Prolyl Hydroxylase in the Prevention of Oxygen-Induced Retinopathy.

Christie Campla, George Hoppe, Minzhong Yu, Juliana Woda, Neal S Peachey, Vara Prasad Josyula, Shaun R Stauffer, Jonathan E Sears

Abstract read
In one paragraph

Article in Journal of medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Christie CamplaOphthalmic Research, Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio 44195, United States.
George HoppeOphthalmic Research, Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio 44195, United States.
Minzhong YuOphthalmic Research, Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio 44195, United States.
Juliana WodaInnovations and Drug Discovery, Cleveland Clinic, Cleveland, Ohio 44195, United States.
Neal S PeacheyOphthalmic Research, Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio 44195, United States.ORCID 0000-0002-4419-7226
Vara Prasad JosyulaInnovations and Drug Discovery, Cleveland Clinic, Cleveland, Ohio 44195, United States.
Shaun R StaufferInnovations and Drug Discovery, Cleveland Clinic, Cleveland, Ohio 44195, United States.ORCID 0000-0002-6332-1827
Jonathan E SearsOphthalmic Research, Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio 44195, United States.ORCID 0000-0002-7007-6938

Funding

RESOURCE/SERVICE CORE C - MOLECULAR INFORMATICS MODULEP30EY025585 · NEI · CLEVELAND CLINIC LERNER COM-CWRU · PI BELA ANAND-APTE · 2016 to 2026
$7.7M
The molecular basis of liver induced retinal blood vessel plasticity.R01EY024972 · NEI · CLEVELAND CLINIC LERNER COM-CWRU · PI JONATHAN E SEARS · 2015 to 2026
$4.0M
BLRD VA IK6 BX005233NEI NIH HHS P30 EY025585NEI NIH HHS R01 EY024972
6 · The paper itself

Abstract

Retinopathy of prematurity (ROP) blinds severely premature infants and is caused by oxygen supplementation. Hypoxia-inducible factor (HIF) stabilization during hyperoxia can prevent oxygen-induced retinopathy (OIR), the experimental correlate of ROP. Stabilization of hepatic HIF-1 alone can prevent OIR while contemporaneously protecting other organ systems, such as the lung and brain, from oxygen toxicity. However, HIF stabilization in central nervous system (CNS) oligodendrocytes reduces myelination. Here, we report the synthesis of small molecules specifically designed to not cross the blood-brain barrier based on a prodrug structure susceptible to hepatic carboxylesterases that release active drug. Twenty compounds were synthesized and rank ordered by Western blot, hypoxia response element binding, and reporter gene analysis. The lead compound prevented OIR, maintained normal CNS myelination, preserved the electroretinogram b-wave, and protected astrocytes. Strategies such as this might be broadly applicable to target specific hepatic functions while limiting off-target effects in other organs.

Indexed as

Hypoxia-Inducible Factor-Proline DioxygenasesOxygenProlyl-Hydroxylase InhibitorsRetinopathy of PrematuritySmall Molecule LibrariesAnimalsAstrocytesHumansLiverMiceHypoxia-Inducible Factor-Proline DioxygenasesOxygenProlyl-Hydroxylase InhibitorsSmall Molecule Libraries

Identifiers

PMID40464542
PMCPMC12202158

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.